The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout
نویسندگان
چکیده
Department of Internal Medicine, Seoul St. Mary’s Hospital, Department of Internal Medicine, Seoul National University Hospital, Seoul, Department of Internal Medicine, Inha University Hospital, Incheon, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine 5 , Department of Internal Medicine, Severance Hospital, Department of Medicine, Hanyang University Medical Center, Seoul, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Pyeongchon, Department of Internal Medicine, Gachon Medical School Gil Medical Center, Incheon, Department of Biostatistics, Seo Kyeong University, Seoul, Korea
منابع مشابه
Diabetes and gout: efficacy and safety of febuxostat and allopurinol
AIM Assess influences of demographics and co-morbidities of gout patients with or without diabetes on safety and efficacy of urate-lowering agents. METHODS Post-hoc analysis of 312 diabetic and 1957 non-diabetic gout patients [baseline serum urate levels (sUA) ≥8.0 mg/dl] enrolled in a 6-month randomized controlled trial comparing urate-lowering efficacy (ULE) and safety of daily xanthine oxi...
متن کاملComparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis
The prevalence of hyperuricemia and gout has been increasing, but the comparative effectiveness and safety of different treatments remain uncertain. We aimed to compare the effectiveness and safety of different treatments for hyperuricemia using network meta-analysis methodology. We systematically reviewed fifteen randomized controlled trials (involving 7,246 patients through January 2016) that...
متن کاملUrate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study
Introduction. Febuxostat, a novel xanthine oxidase inhibitor for the treatment of symptomatic hyperuricemia, showed superiority over allopurinol in the reduction of serum uric acid levels in pivotal studies. Whether this holds true the FORTE (febuxostat in the oral urate lowering treatment: effectiveness and safety) study was conducted to evaluate treatment with febuxostat under daily practice ...
متن کاملThe efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
BACKGROUND The incidence of gout rises with increasing age. Management of elderly (≥65 years) gout patients can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and concomitant medication use. However, there is little data specifically addressing the efficacy and safety of available urate-lowering therapies (ULT) in the elderly. The objecti...
متن کاملFebuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
OBJECTIVES This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout. The primary efficacy end-point was reduction to and maintenance of serum urate (sUA) levels < 6.0 mg/dl. METHODS Subjects who completed a previous 28-day study were entered into an open-label extension study and initially received febuxostat 80 mg daily. B...
متن کاملThe urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
INTRODUCTION The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial. METHODS Subjects (n = 2,269) were randomized to febuxostat 40 mg or 80 mg, or allopurinol 300 mg (200 mg in moderate renal impairment). Endpoints included the proportion of all subje...
متن کامل